Ionis Pharmaceuticals, Inc.
General ticker "IONS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $12.4B (TTM average)
Ionis Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -27.4%.
Estimated limits based on current volatility of 2.1%: low 42.53$, high 44.34$
Factors to consider:
- Total employees count: 1402 (+31.2%) as of 2025
- Top business risk factors: Market acceptance, Market competition, Clinical trial failure, Construction delays, Capital shortage
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [47.25$, 93.62$]
- 2026-12-31 to 2027-12-31 estimated range: [38.00$, 78.04$]
Financial Metrics affecting the IONS estimates:
- Negative: with PPE of -41.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.10 <= 2.37
- Positive: 12.78 < Shareholder equity ratio, % of 13.88 <= 25.20
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Negative: 0.33 < Interest expense per share per price, % of 0.71
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: -2.60 < Investing cash flow per share per price, % of -2.17
Short-term IONS quotes
Long-term IONS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $787.65MM | $705.14MM | $943.71MM |
| Operating Expenses | $1,141.38MM | $1,180.22MM | $1,325.39MM |
| Operating Income | $-353.73MM | $-475.08MM | $-381.68MM |
| Non-Operating Income | $19.77MM | $15.01MM | $2.08MM |
| Interest Expense | $81.46MM | $90.45MM | $90.54MM |
| R&D Expense | $899.62MM | $901.53MM | $915.62MM |
| Income(Loss) | $-333.96MM | $-460.07MM | $-379.60MM |
| Taxes | $32.32MM | $-6.17MM | $1.79MM |
| Net Income(Loss)* | $-366.29MM | $-453.90MM | $-381.39MM |
| Stockholders Equity | $386.69MM | $588.35MM | $489.09MM |
| Inventory | $7.44MM | $12.51MM | $10.05MM |
| Assets | $2,990.07MM | $3,003.68MM | $3,523.84MM |
| Operating Cash Flow | $-307.51MM | $-500.95MM | $-268.58MM |
| Capital expenditure | $28.01MM | $45.28MM | $51.44MM |
| Investing Cash Flow | $-214.13MM | $-134.03MM | $-277.78MM |
| Financing Cash Flow | $644.08MM | $478.06MM | $675.84MM |
| Earnings Per Share** | $-2.56 | $-3.04 | $-2.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.